Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST)

Circulation

Volumn 103, Issue 16, 2001, Pages 2055-2059

  Deswal, A ^a   Petersen, N J ^a   Feldman, A M ^a   Young, J B ^a   White, B G ^a   Mann, D L ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Heart failure; Tumor necrosis factor

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 6; PIPERANOMETOZINE; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DISEASE COURSE; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; STATISTICAL ANALYSIS;

EID: 0035942264     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.16.2055     Document Type: Article

References (17)

1. Cytokines in heart failure: Pathogenetic mechanisms and potential treatment
2. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)
3. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension
4. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
5. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure
6. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
7. Basic mechanisms in heart failure: The cytokine hypothesis
8. Plasma cytokine parameters and mortality in patients with chronic heart failure
9. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators
10. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-α in vitro
11. Cutting edge: A dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion
12. Tumor necrosis factor-αconverting enzyme and tumor necrosis factor-α in human dilated cardiomyopathy
13. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
14. Increased soluble tumor necrosis factor receptor levels in the serum of elderly people
15. Estrogen modulates the expression of tumor necrosis factor-α mRNA in phorbol ester-stimulated human monocytic THP-1 cells
16. Racial differences in the outcome of left ventricular dysfunction
17. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure